The buyback accelerates capital return but provides no new operational information. Monitor the final share count upon June 30 settlement for the exact EPS impact. With $3B remaining authorization, the pace of future execution matters more than this single transaction. The filing.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $55.89entry
- T+1 · 6mo ago +1.66%α +2.31% · $56.82
- T+5 · 6mo ago +3.10%α +1.48% · $57.62
- T+20 · 5mo ago −16.33%α −18.52% · $46.76
- T+60 · 3mo ago −8.04%α −12.62% · $51.40
Price Chart
How similar events traded
Executive Summary
Boston Scientific entered into a $2B accelerated share repurchase (ASR) agreement with JPMorgan to repurchase its common stock, receiving ~30.4M shares initially (80% of $2B at $52.68 close). The program is part of a previously authorized $5B buyback, with final settlement expected by June 30, 2026. The ASR is expected to add $0.02 to FY2026 adjusted EPS, but the filing provides no other financial data, it is a routine capital allocation announcement with a modest EPS tailwind.
Key Facts
- $2B accelerated share repurchase agreement with JPMorgan Chase Bank announced May 18, 2026
- Initial delivery of ~30.4M shares (~80% of $2B at May 15 close of $52.68)
- Final settlement expected by June 30, 2026; $3B remains under the $5B authorization
- Expected net impact to FY2026 adjusted EPS is $0.02 accretive to prior guidance
Financial Impact
$2.0 billion ASR with ~30.4 million initial shares; $0.02 accretive to FY2026 adjusted EPS
Risk Factors
- ASR final share count depends on VWAP during the term, lower price means more shares retired, but that reflects underlying weakness
- Buyback does not offset operational challenges if future earnings disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000885725-26-000042 |
| Exhibit: exhibit991-pressrelease_fi.htm | 0000885725-26-000042 |
| Document: 0000885725-26-000042-index-headers.html | 0000885725-26-000042 |
| Document: 0000885725-26-000042-index.html | 0000885725-26-000042 |
| Document: 0000885725-26-000042.txt | 0000885725-26-000042 |
Track record
23 reports on BSX
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 2/10 Entry $43.28 Now $43.03 −0.58% settles Dec 17
- Oct 28, 202620d ago 8-K Bearish 6/10 No price data
- Oct 28, 202620d ago Press Release Bearish 5/10 Entry $42.43 Now $43.03 −1.41% settles Nov 25
- Oct 23, 202625d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.03 +5.82% settles Nov 20
- Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.03 +3.49% ▲ +10.20% +11.54% vs SPY
- Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.03 +3.56% ▲ +0.25% +0.93% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.03 −10.50% ▼ −9.21% −9.57% vs SPY
- Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.03 +10.67% ▲ +9.24% +10.44% vs SPY
- Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.03 −12.20% ▼ −8.35% −9.66% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.03 −14.72% ▼ −10.86% −9.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers